AnaptysBio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
11analysts covering
FY EPS (est.)
-$0.23next fiscal year
Monitoring Framework
Key Performance Indicators
Jemperli (dostarlimab) Royalties Quarterly24.7MTarget: >$390 million annualized by 2029
Cash, Cash Equivalents and Investments Quarterly286.5MTarget: Maintain sufficient runway for royalty management operations
Collaboration Revenue Quarterly25.6MTarget: Grow through Jemperli expansion and imsidolimab commercialization
Watch Items
- Imsidolimab PDUFA DateTrigger: December 12, 2026Action: Monitor Vanda Pharmaceuticals' regulatory progress and BLA/MAA preparation for Generalized Pustular Psoriasis (GPP).
- GSK Jemperli LitigationTrigger: Trial or settlement resolutionAction: Track legal proceedings in Delaware Chancery Court regarding the principal contractual dispute with GSK/Tesaro.
- Sagard Royalty Monetization PaydownTrigger: Accrual of ~$275 million through Q1 2026Action: Anticipate full paydown of the remaining ~$325 million non-recourse debt monetization by the end of Q2 2027 to unlock direct cash flows.
Research as of 20 Jun 2026